Literature DB >> 2194029

Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol.

S S Steiner1, A J Friedhoff, B L Wilson, J R Wecker, J P Santo.   

Abstract

This randomized, double-blind parallel study compared the effects of atenolol, captopril, enalapril and propranolol in 360 men with mild-to-moderate essential hypertension. Patients were titrated until diastolic blood pressure (Korotkoff phase V) decreased by at least 10 mmHg or to 90 mmHg or less. Quality of life assessments, based on validated psychometric questionnaires and objective measurements of cognitive function, occurred after three study phases: placebo run-in (3-5 weeks), titration (1-4 weeks), and maintenance (4 weeks). After four weeks of maintenance therapy, atenolol, captopril and enalapril generally had equivalent effects on quality of life, as measured by psychometric questionnaires, whereas propranolol consistently evidenced worsening or less improvement. Global scores of distressing psychological symptoms differed as a function of specific treatment (P = 0.01), with improvements significantly better for the atenolol, captopril and enalapril groups as compared with the propranolol group. There were no statistically significant differences among treatments for changes in cognitive function at maintenance. Thus, the quality of life questionnaires differentiated among drugs of the same class, indicating that selection among antihypertensive drugs should be based on their specific qualities, not on general class characteristics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2194029

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  34 in total

1.  Assessing the responsiveness of a quality-of-life instrument and the measurement of symptom severity in essential hypertension.

Authors:  M C Reilly; A S Zbrozek
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

2.  Do patients with prostatic cancer require treatment?

Authors:  R P Huben
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

Review 3.  Selective versus nonselective beta adrenoceptor antagonists in hypertension.

Authors:  L M Van Bortel; A J Ament
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

4.  Validity and reliability of the Spanish version of the Psychological General Well-Being Index.

Authors:  X Badia; F Gutiérrez; I Wiklund; J Alonso
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

Review 5.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 6.  Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Authors:  I Côté; J P Grégoire; J Moisan
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

7.  Quality of life evaluation of antihypertensive drugs.

Authors:  C J Bulpitt; A E Fletcher
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 8.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol.

Authors:  T Mengden; B Bättig; M Schubert; T Jeck; B Weisser; C Buddeberg; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 10.  A critical review of dimension-specific measures of health-related quality of life in cross-cultural research.

Authors:  M J Naughton; I Wiklund
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.